Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies lapatinib to see how well it works in treating young patients
with recurrent or refractory central nervous system (CNS) tumors. Lapatinib may stop the
growth of tumor cells by blocking the enzymes necessary for their growth.